ArticleCancer science2010
Vasohibin-1 as a potential predictor of aggressive behavior of ductal carcinoma in situ of the breast.
Article in Cancer science, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 43 citations in OpenAlex.
- Dynamic changes in vasohibin and nitric oxide signaling following surgical resection of head and neck squamous cell carcinoma.World journal of surgical oncology · 2025Article
- Review
- High preoperative plasma vasohibin-1 concentration predicts better prognosis in patients with non-small cell lung carcinoma.Health science reports · 2018Article
- Association between TAp73, p53 and VASH1 expression in lung adenocarcinoma.Oncology letters · 2018Article
- Vasohibin-1 as a novel microenvironmental biomarker for patient risk reclassification in low-risk prostate cancer.Oncotarget · 2018Article
- The roles of vasohibin and its family members: Beyond angiogenesis modulators.Cancer biology & therapy · 2017Review
- MicroRNA-4530 promotes angiogenesis by targeting VASH1 in breast carcinoma cells.Oncology letters · 2017Article
- Increased vasohibin-1 expression is associated with metastasis and poor prognosis of renal cell carcinoma patients.Laboratory investigation; a journal of technical methods and pathology · 2017Article
- The effect of Vasohibin-1 expression and tumor-associated macrophages on the angiogenesis in vitro and in vivo.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- The angiogenesis regulator vasohibin-1 inhibits ovarian cancer growth and peritoneal dissemination and prolongs host survival.International journal of oncology · 2015Article
- Vasohibin-1 expression detected by immunohistochemistry correlates with prognosis in non-small cell lung cancer.Medical oncology (Northwood, London, England) · 2014Article
- Urinary and plasma levels of vasohibin-1 can predict renal functional deterioration in patients with renal disorders.PloS one · 2014Article
- Article
- In vivo delivery of siRNA targeting vasohibin-2 decreases tumor angiogenesis and suppresses tumor growth in ovarian cancer.Cancer science · 2013Article
- Hexokinase II in breast carcinoma: a potent prognostic factor associated with hypoxia-inducible factor-1α and Ki-67.Cancer science · 2013Article
- The prognostic significance of vasohibin-1 expression in patients with prostate cancer.British journal of cancer · 2013Article
- Article
- The vasohibin family: a novel family for angiogenesis regulation.Journal of biochemistry · 2013Review
- Vasohibin-1 and vasohibin-2 expression in gastric cancer cells and TAMs.Medical oncology (Northwood, London, England) · 2012Article
- Tumor angiogenesis: pericytes and maturation are not to be ignored.Journal of oncology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vasohibin-1 is a recently identified negative feedback regulator of angiogenesis induced by VEGF-A and bFGF. In this study, we first evaluated mRNA expression of vasohibin-1 and CD31 in 39 Japanese female breast carcinoma specimens including 22 invasive ductal carcinoma (IDC) and 17 ductal carcinoma in situ (DCIS) using a real-time quantitative RT-PCR (QRT-PCR) with LightCycler system. In addition, we also immunolocalized vasohibin-1 and CD31 and compared their immunoreactivity to nuclear grades and histological grades of 100 carcinoma cases (50 IDC and 50 DCIS). There were no statistically significant differences of CD31 mRNA expression and the number of CD31 positive vessels between DCIS and IDC (P = 0.250 and P = 0.191, respectively), whereas there was a statistically significant difference in vasohibin-1 mRNA expression and the number of vasohibin-1 positive vessels in DCIS and IDC (P = 0.022 and P < or = 0.001, respectively). There was a significant positive correlation between vasohibin-1 mRNA level and Ki-67 labeling index in DCIS (r(2) = 0.293, P < or = 0.001). In addition, vasohibin-1 mRNA expression was correlated with high nuclear and histological grades in DCIS cases and a significant positive correlation was detected between the number of vasohibin-1 positive vessels and Ki-67 labeling index or nuclear grade or Van Nuys classification of carcinoma cells (P < or = 0.001, respectively). These results all indicate the possible correlation between aggressive biological features in DCIS including increased tumor cell proliferation and the status of neovascularization determined by vasohibin-1 immunoreactivity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.